Unnecessary axillary surgery

kira66715

Found this article recently: hopefully things are changing since 2008

http://www.ncbi.nlm.nih.gov/pubmed/21930999

Arch Surg. 2011 Sep;146(9):1029-33.
Unnecessary axillary surgery for patients with node-negative breast cancer undergoing total mastectomy.
Olaya W, Morgan JW, Lum SS.
Source
Division of Surgical Oncology, Department of Surgery, School of Medicine, Loma Linda University, Loma Linda, CA 92350, USA.
Abstract
OBJECTIVE:
To identify factors associated with the use of axillary lymph node dissection (ALND) as the initial axillary staging in node-negative breast cancer patients undergoing total mastectomy.

DESIGN:
California Cancer Registry study.

SETTING:
Academic research.

PATIENTS:
Women treated with total mastectomy for Tis, T1, or T2 node-negative breast carcinoma treated between January 1, 2004, and December 31, 2008.

MAIN OUTCOME MEASURES:
Proportions of patients who underwent ALND without prior sentinel lymph node dissection were compared by demographic characteristics.

RESULTS:
Of 18,238 women treated with total mastectomy for Tis, T1, or T2 node-negative breast carcinoma, 35.1% underwent initial axillary staging by ALND without prior sentinel lymph node dissection. On multivariable analyses, patients were significantly more likely to undergo ALND if they had T2 disease or were 65 years or older, were hormone receptor negative, of Hispanic or Asian/Pacific Islander race/ethnicity, of lower socioeconomic quintile, operated on during earlier years of the study period, and not treated by a hospital cancer program approved by the American College of Surgeons.

CONCLUSIONS:
More than one-third of patients in California who underwent total mastectomy for treatment of early-stage node-negative breast carcinoma received ALND without prior sentinel lymph node dissection; furthermore, certain subsets of patients have higher odds of undergoing ALND alone. To avoid the unnecessary morbidity of ALND in early-stage breast carcinoma, further research is required to elucidate how tumor, patient, and system factors can be modified to improve delivery of optimal breast cancer care.

Comment in
Arch Surg. 2011 Sep;146(9):1033-4.